DOCSLIB.ORG

Discontinue Stress, Discontinue Stress Ulcer Prophylaxis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discontinue Stress, Discontinue Stress Ulcer Prophylaxis Volume 22, Number 1 January 2008 Drugs & Therapy B � U � L � L � E � T � I � N FORMULARY UPDATE PRESCRIBING The Pharmacy and Therapeutics Committee met November 20, 2007. Discontinue stress, discontinue 2 drugs were added in the Formu- lary, and 4 drugs or dosage forms stress ulcer prophylaxis were deleted. 5 drugs or dosage tress ulcers are superficial lesions should be discontinued in patients with- forms were designated nonformulary involving the mucosal layer of the out an additional indication for use (eg, and not available. Criteria for use S stomach that appear after major stressful gastrointestinal reflux disease [GERD] or were changed for 3 drugs. events.1 Critically ill patients admitted history of GI bleed). When a patient trans- to intensive care units (ICUs) are at an fers or is discharged from an ICU, there is ◆ ADDED increased risk for suffering from compli- an opportunity to discontinue SUP. Ambrisentan cations related to stress ulceration.2 As An audit of SUP use in the ICUs at (Letairis® by Gilead Sciences)* such, stress ulcer prophylaxis (SUP) is Shands at UF was recently conducted. *Restricted to patients approved for the appropriate for many critically ill patients. Thirty adult patients receiving SUP were Letairis Education and Access Program SUP is defined as any medication used followed during their hospital admis- to prevent formation of stress ulcers and sion, beginning upon admission to the Anidulafungin includes antacids, sucralfate, prostaglan- surgical intensive care unit (SICU). When (Eraxis® by Pfizer)† din analogues, histamine H2-receptor mechanical ventilation and coagulopathy †Restricted to approval by the ID antagonists, and proton-pump inhibitors were no longer present, SUP was no lon- Consult Service, Dr. Wingard, or the (PPIs). Although these therapies are con- ger considered necessary. Other reasons Antimicrobial Management Program sidered effective, there are disadvantages to continue SUP included acid suppres- associated with their use. A higher gas- sion therapy prior to admission, or a past ◆ DELETED tric pH is associated with gastric microbi- medical history of GERD or a GI bleed. Aprotinin (Trasylol® by Bayer)‡ al growth, tracheobronchial colonization, Upon transfer from the SICU, 73% of 3 patients were continued inappropriately, ® ‡ and nosocomial pneumonia. Unnecessary Caspofungin (Cancidas by Merck) use of acid suppression therapy has been 16% continued appropriately, and only Itraconazole, Intravenous associated with the development of com- 11% discontinued appropriately. A similar (Sporanox® by Ortho Biotech)‡ munity-acquired pneumonia, as well as evaluation was conducted for 30 patients community-acquired Clostridium difficile in the medical intensive care unit (MICU). Ranitidine Effervescent Tablets infections.4,5 Both studies were conducted Upon transfer from the MICU, 36% were (Zantac® Efferdose by Glaxo- in outpatients and found an association continued inappropriately and 64% con- SmithKline)‡ between the use of acid suppression tinued appropriately. SUP was discontin- ‡Nonformulary and Not Available therapy and infection.4,5 In addition, long- ued appropriately in none of the patients. term PPI use, particularly at high-doses, The evaluation also indicated that some ◆ NONFORMULARY AND has been associated with an increased patients (ie, 15% from the SICU and 5% NOT AVAILABLE risk of hip fracture (ie, osteoporosis).5 SUP from the MICU) were discharged from the Ramelteon (Rozerem® by Takeda also increases the number of medications hospital on acid suppression therapy with Pharmaceuticals) a patient receives, as well as the cost of no indication for continued use. their treatment.3 The results of this audit show that ◆ CRITERIA-FOR-USE CHANGES Several risk factors have been identi- some critically ill patients are unneces- fied for the development of stress ulcers, sarily continued on SUP upon discharge Altretamine (Hexalen® by MGI including respiratory failure, coagulopa- from the ICUs. SUP should be discontin- Pharma)§ thy, hypotension, sepsis, hepatic failure, ued upon elimination of risk factors. §Requires a Chemotherapy Order renal failure, surgery, burns, and major Appropriate use of SUP may translate Form; Nonformulary. trauma.2 A prospective, multi-center to a reduction in adverse events and Ceftriaxone (Rocephin® & generics)** cohort study conducted by Cook and healthcare expenditures. By Sarah Bush, PharmD ** colleagues identified 2 independent risk Resticted:Cannot be used in infants factors for bleeding. The strongest risk (References listed on page 4) 28 days old or less factors are mechanical ventilation for Meningococcal Polysaccharide more than 48 hours and coagulopathy, Diphtheria Toxoid Conjugate Vac- defined as a platelet count less than ◆ ® †† 3 cine (Menactra by Sanofi Pasteur) 50,000 mm , an International Normalized INSIDE THIS ISSUE ††Can be used in patients from 2–55 Ratio (INR) of greater than 1.5, or a partial thromboplastin time of greater than 2 years of age ◆ P&T 2007 times the control value.2 (continued on next page) When risk factors no longer exist, SUP Formulary update, from page 1 Anidulafungin was added in the For- significant higher rate compared with Ambrisentan was approved by the mulary as the sole representative of the either of the other treatment arms. FDA in June 2007 with a labeled indi- echinocandin antifungal agents. Caspo- This trend of higher mortality with cation for the treatment of pulmonary fungin was deleted from the Formulary aprotinin was observed throughout arterial hypertension (WHO Group 1) and designated nonformulary and not the study. Although less blood was in patients with WHO class II or III available. Micafungin (Mycamine®) re- used in the aprotinin arm compared symptoms to improve exercise capac- mains nonformulary and not available. with either of the other treatments, ity and delay clinical worsening. It is The echinocandins were originally more deaths due to hemorrhage were an alternative to bosentan (Tracleer®), reviewed in November 2006. At that observed in the aprotinin arm. The which is listed in the Formulary but time, caspofungin, micafungin, and data safety monitoring board con- restricted to patients who have been anidulafungin were deemed equiva- cluded that continued enrollment of approved for bosentan’s restricted lent. Caspofungin was selected as the patients was unlikely to change these drug distribution program. formulary agent, and micafungin and findings. Due to the risk of hepatic injury anidulafungin were designated nonfor- The FDA is currently evaluating and birth defects, ambrisentan also is mulary and not available. these results and determining what only distributed through a restricted The echinocandins were re-evalu- additional actions are needed (eg, drug distribution program (ie, the Le- ated because increased competition further modification of the product tairis Education and Access Program among these products has resulted in labeling or permanently pulling the [LEAP]). Prescribers and pharma- cost reductions. Little new evidence drug from the market). These data cists must call 866-663-LEAP (5327) has been published in the last year. from a randomized controlled trial to enroll patients. In order to stock There is a study showing equivalency are consistent with an observational ambrisentan, hospitals must sign an of micafungin at doses of 100 mg and study published approximately a year agreement that it will be dispensed 150 mg once daily with standard doses ago that also found a higher rate of only to patients who are already en- of caspofungin for the management of mortality with aprotinin. The Director rolled in the restricted drug distribu- candidemia and invasive candidiasis. In of the Office of New Drugs was quot- tion program (ie, LEAP). addition, results from a study compar- ed as saying, “FDA cannot identify a Compared with bosentan, ambrisen- ing anidulafungin to fluconazole in the specific patient population where we tan costs roughly the same (ie, approxi- management of invasive candidiasis believe the benefits of using Trasylol® mately $50,000 per year). Bosentan is were published, and anidulafungin was [aprotinin] outweigh the risks.” given twice a day, while ambrisentan found to be noninferior to fluconazole. The FDA’s decision not to recall is given once a day. Anidulafungin was selected for the aprotinin was intended to prevent There is limited information pub- Formulary because it results in the a shortage of alternatives (ie, amin- lished on the efficacy of ambrisentan; most potential cost savings. ocaproic acid and tranexamic acid). but there is a theoretical pharmaco- Aprotinin is a proteolytic enzyme Shands at UF has been able to get an logic advantage for ambrisentan; it is from bovine lung that has a labeled ample supply of aminocaproic acid more specific for blocking endothelin indication for the prevention of blood and tranexamic acid to be used as an A, which is responsible for vasocon- loss and transfusion in patients under- alternative. Based on the new warn- striction and tissue damage in the going surgery requiring cardiopulmo- ings and the availability of alterna- pulmonary vasculature. nary bypass. It was deleted from the tives agents, the P&T Committee Both bosentan and ambrisentan are Formulary and designated nonformu- determined that the continued use pregnancy risk category X because of lary and not available after marketing of aprotinin is not warranted at this their teratogenic potential. Both also was suspended based on recent safety
Load more

Recommended publications
  • Critical Care and Resuscitation  Volume 15 Number 2  June 2013 147 BRIEF COMMUNICATION
    BRIEF COMMUNICATION Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting KJ Farley, Kerryn L Barned and Tim M Crozier Stress ulceration describes injury of the gastrointestinal (GI) ABSTRACT mucosa in response to stressors such as hypoperfusion, hypoxia, reperfusion, and imbalance between gastric acid Objective: To determine how frequently stress ulcer productionCrit Care and Resusc mucosal ISSN: defence 1441-2772 mechanisms. 13 June 1 Endoscopic prophylaxis (SUP) medications prescribed in the intensive evidence2013 15of 2stress 147-151 ulceration is seen in most patients soon care unit are inappropriately continued on the ward and on ©Crit Care Resusc 20132 afterwww.jficm.anzca.edu. admission to the au/aaccm/journal/publi-intensive care unit, with clinical hospital discharge. severitycations.htm ranging from endoscopic findings only to life- Design: Retrospective cohort study; chart review. Brief communication threatening haemorrhage. Certain subgroups of critically ill Setting: Two Australian ICUs: one tertiary centre and one patients have increased risk of clinically significant GI metropolitan centre. 3,4 bleeding (Table 1), with rates of 3.7% in those with Participants: We included 387 adult, non-pregnant coagulopathy and those needing > 48 hours of mechanical patients who were admitted to the ICU between 1 February ventilation, compared with 0.1% in patients without these 2011 and 31 March 2011 and who survived to hospital 5 risk factors. Clinically significant GI bleeding should be discharge. prevented where possible as it is associated with a signifi- Main outcome measures: Rate of unnecessary cant attributable morbidity, mortality6,7 and increased continuation of ICU-prescribed SUP medications on the length of stay in the ICU.7 ward and on discharge from hospital.
    [Show full text]
  • Updates in Stress-Ulcer Prophylaxis
    Updatesinstressulcerprophylaxis:Is pharmacologicalprophylaxisstill indicated? RubenDVillanueva,PharmD,BCCCP,BCPS Assistantprofessor OUHSCCollegeofPharmacy TraumaCriticalCare OUMedicalCenter 1 Objectives • Describethepathophysiologyofstressulcersinthe criticallyill • Compareandcontrastcurrentstressulcerprophylaxis guidelines • Summarizerecentstressulcerprophylaxisliterature • Determineacriticallyillpatient’scontinuedneedfor stressulcerprophylaxis 2 PreͲAssessment Whichofthefollowingistheunderlying pathophysiologicprocessforthedevelopmentof stressulcersintheICU? A) GIhypoperfusion B) Anemia C) Infection D) Hypersecretorystate 3 PreͲAssessment Whichofthefollowinghavebeenidentifiedas independentriskfactorsforclinicallysignificantGI bleedingincriticallyillpatients? A) Sepsis B) Organtransplant C) Vasoactivemedications D) Renalreplacementtherapy 4 PreͲAssessment Enteralnutritionwouldlikelybesufficientforstress ulcerprophylaxisinwhichofthefollowingscenarios? A) Mechanicallyventilatedpatientreceivingcontinuous renalreplacementtherapywithanINRof2 B) MechanicallyventilatedTBIpatientwithout intracranialhypertension C) Mechanicallyventilatedpatientwithchronicliverand kidneydisease,COPD,andreceivingcorticosteroids D) Mechanicallyventilatedpatientwithoutsignificant PMH,anINRof1.9andonnorepinephrine 5 UpdatesinStressUlcerProphylaxis BACKGROUND& PATHOPHYSIOLOGY 6 Background Stressrelatedmucosaldisease/damage • Representsacontinuum – Asymptomaticsuperficiallesionstoclinically significantGIbleeding(GIB) • Twotypes – Stressrelatedinjury – Stressulcers •
    [Show full text]
  • 1. ICU Protocol Management Cover
    ICU Management Protocols Published by Malaysian Society of Intensive Care Printed by Malaysian Society of Intensive Care (MSIC) Unit 1.6, Level 1, Enterprise 3B Technology Park Malaysia Jalan Innovasi 1, Bukit Jalil 57000 Kuala Lumpur, Wilayah Persekutuan Website: www.msic.org.my In collabration with Ministry of Health Malaysia Copyright © Malaysian Society of Intensive Care Pusat Kebangsaan ISBN Malaysia ISBN 978-967-11415-4-0 Cover design by Nabil bin Ali Disclaimer: The content of this book has been produced in good faith to guide medical practitioners. However practitioners are advised to keep abreast the current evidence-based practices that are constantly evolving and to take into account the local issues and limitations. Foreword There are many aspects in the care and management of the critically ill patient. As clinicians we need to keep abreast with the most current evidence-based practices to ensure optimal patient care and safety. This is an update of the management protocol book written in 2012, to facilitate clinicians in the management of the critically ill. Each protocol was developed with careful consideration of current evidence as well as the practical application and cost containment within our institutions. The algorithms in the protocols are simple to use and can be easily implemented. There are great concerns on the rise of multi-drug resistant organisms. We know that critically ill patients are at high risk of acquiring infections. To address this, a protocol on prevention and control of multi-drug organisms is included. This protocol materialised due to the many hours of discussion and exchange of opinions.
    [Show full text]
  • In Haemorrhagic Shock Induced Gastric Lesions
    Gut: first published as 10.1136/gut.29.6.826 on 1 June 1988. Downloaded from Gut, 1988, 29, 826-829 Ranitidine and oxygen derived free radical scavengers in haemorrhagic shock induced gastric lesions E C TSIMOYIANNIS, C J SARROS, J C TSIMOYIANNIS, K MOUTESIDOU, G AKALESTOS, AND 0 B KOTOULAS From the Department ofSurgery, G Hatzikosta General Hospital ofIoannina and Department ofAnatomy, loannina University Medical School, loannina, Greece SUMMARY The role of oxygen derived free radicals in gastric lesions induced by haemorrhagic shock and the protective effect of oxygen radical scavengers, allopurinol and ranitidine, were investigated. Forty five rabbits underwent haemorrhagic shock for 30 minutes and reinfusion ofshed blood. They were killed 30 minutes later. The animals were divided in five groups: A (n=10): Control, B (n=10): intravenous ranitidine pretreatment, C (n=10): oral allopurinol, 24 and 2 h before surgery, D (n= 10): intravenous pretreatment with superoxide Dismutase plus catalase, E (n=5): 60 minute haemorrhagic shock without reinfusion and treatment. Erosions and/or petechiae in all animals in Group A were observed. Three animals in group B and C and 2 in group D (p<0O005, p<0-001) had gastric lesions. The lesions in the pretreatment groups were significantly smaller than in controls. Oxygen radicals plus HCI play an important role in shock induced gastric lesions. Oxygen radical antagonists show a significant protective role. http://gut.bmj.com/ Clinical and experimental studies have shown that the role of oxygen derived free radicals in haemorr- haemorrhagic shock often is followed by rapid hagic shock induced gastric lesions and the protective development of gastric mucosal lesions.' 3 Gastric effect of oxygen radical scavengers, allopurinol (a blood flow is considerably reduced during haemorr- xanthine oxidase inhibitor) and ranitidine (an H2 on October 6, 2021 by guest.
    [Show full text]
  • Download (197Kb)
    Idanosa and Kahn Critical Care 2012, 16:305 http://ccforum.com/content/16/1/305 JOURNAL CLUB CRITIQUE Beyond checklists: Using clinician prompts to achieve meaningful ICU quality improvement Osamudiamen Idahosa1 and Jeremy M Kahn*1-3 University of Pittsburgh Department of Critical Care Medicine: Evidence-Based Medicine Journal Club, edited by Sachin Yende Expanded abstract hospital mortality, ICU length of stay and ventilator Citation associated pneumonia. Weiss CH, Moazed F, McEvoy CA, et al. Prompting physicians to address a daily checklist and process of care Results and clinical outcomes: a single-site study. Am J Respir One hundred and forty prompted group patients were Crit Care Med 2011, 184:680-686. Epub 2011 May 26. compared with 125 concurrent control patients and 1283 PubMed PMID: 21616996. pre-intervention patients. Compared with control patients, patients admitted to the service with prompting Background experienced increased ventilator-free days, decreased Checklists may reduce errors of omission for critically ill empirical antibiotic and central venous catheter duration, patients. and increased rates of deep vein thrombosis and stress ulcer prophylaxis. Prompted group patients had lower Methods risk-adjusted ICU mortality compared with the control Objective: To determine whether prompting to use a group (odds ratio, 0.36; 95% confi dence interval, 0.13– checklist improves process of care and clinical outcomes. 0.96; P = 0.041) and lower hospital mortality compared Design: Prospective, concurrently-controlled cohort study with the control group (10.0 vs. 20.8%; P = 0.014), which with additional historical controls. remained signifi cant after risk adjustment (adjusted odds Setting: Medical intensive Care Unit (MICU) of a tertiary ratio, 0.34; 95% confi dence interval, 0.15–0.76; P = 0.008).
    [Show full text]
  • Severe Legionnaire's Disease Requiring Intensive Care Treatment
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Erasmus University Digital Repository I‘he Netherlands JOURNALOF MEDICINE ELSEVTER NetherlandsJournal of Medicine 4Y (I 996) I Y6620 I Original article Severe Legionnaire’s disease requiring intensive care treatment I.C. van Riemsdijk-van Overbeeke s’, B. van den Berg ’ Abstract Bwkgwund: Legionnaire’s disease is well known as severe pneumonia requiring intensive care treatment in many cases. In this study the clinical course is described of patients admitted to the medical ICU of the University Hospital of Rotterdam for respiratory distress due to Legionnaire’s disease. Methods: From the register of admissions to the medical ICU all patients suffering from Legionnaire’s disease were identified. All data on clinical signs and symptoms present on admission were collected. The circumstances in which the infections were contracted were sought, as well as the tests establishing the diagnosis. The occurrence of various organ failures and complications were noted, as were the causes of death on the KU. Resdts: From 1978 till 1995 the diagnosis of Legionellu pneumonia was made in I7 patients admitted to the ICU: in I3 patients a community-acquired infection was established. As in I2 patients Legionnaire‘s disease was diagnosed on serological tests, it took several weeks before the diagnosis could be established in these patients. In all patients the circumstances predisposing to Legionnaire’s disease were noted. Respiratory distress was present in all patients, ventilatory support was required in 14. Apart from this, both profound shock and renal failure were commonly encountered. As complications jaundice, rhabdomyolysis and polyneuropathy were frequently noted.
    [Show full text]
  • Guideline for Stress Ulcer Prophylaxis in the Intensive Care Unit
    CLINICAL GUIDELINES DANISH MEDICAL JOURNAL Guideline for Stress Ulcer Prophylaxis in the Intensive Care Unit Kristian Rørbæk Madsen, Kristian Lorentzen, Niels Clausen, Emilie Øberg, Peter Roy Casparij Kirkegaard, Nana Maymann-Holler & Morten Hylander Møller. This guideline has been approved by the Danish Society of Anesthesiology and to Danish conditions are few. Thus the current incidence of stress Intensive Care Medicine (DASAIM) and the Danish Society of Intensive Care Medicine ulcer bleeding in ICU patients is largely unknown. (DSIT) 26 January 2014 Correspondence: Kristian Rørbæk Madsen, Department of Anesthesiology and Risk factors Intensive Care, Odense University Hospital, Soendre Boulevard 29, 5000 Odense C, In a prospective multicenter cohort study (n=2256) by Cook et al, Denmark risk factors for clinically important GI bleeding were mechanical E-mail: [email protected] ventilation for more than 48 hours (odds ratio 15.6) and coagulopathy (odds ratio 4.3) 3. Other commonly cited, but less Conflicts of interests: Morten Hylander Møller is the initiator of the “SUP-ICU re- validated risk factors include severe sepsis and septic shock as search programme” (www.sup-icu.com). The remaining authors reported no con- flicts of interests. stated by the Surviving Sepsis Campaign guidelines; head or spinal trauma, hepatic failure, renal failure, major burns, organ trans- plantation, high dose glucocorticoid therapy, previous peptic 1,10 Dan Med J 2014;61(3):C4811. ulcer disease or upper GI bleeding . Last literature review: Nov 1 2013 Prognosis Limitations : Applies to patients aged > 18 years Stress ulcer bleeding is a serious complication. Cook et al. demon- strated a mortality rate of 49%, mostly from decompensation of List of abbreviations: an underlying condition or multiorgan failure, compared to 9% for H2RA = histamine-2-receptor antagonist patients without GI bleeding 3.
    [Show full text]
  • Confidential: for Review Only Efficacy and Safety of Gastrointestinal Bleeding Prophylaxis in Critically Ill Patients: Systematic Review and Network Meta-Analysis
    BMJ Confidential: For Review Only Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis Journal: BMJ Manuscript ID BMJ-2019-052088 Article Type: Research BMJ Journal: BMJ Date Submitted by the 08-Aug-2019 Author: Complete List of Authors: Wang, Ying; Beijing Chao-Yang Hospital, Capital Medical University, Department of Pharmacy YE, ZHIKANG; McMaster University, Department of Health Research Methods, Evidence and Impact Ge, Long; School of Public Health, Lanzhou University, Evidence Based Social Science Research Center; School of Basic Medical Sciences, Lanzhou University, Evidence Based Medicine Center Siemieniuk, Reed; McMaster University, Health Research Methods, Evidence, and Impact Wang, Xin; Beijing Chaoyang Hospital, Capital Medical University, Beijing, China Wang, Yingkai; Beijing Chaoyang Hospital, Capital Medical University, Beijing, China Hou, Liangying; Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China Ma, Zhuo; Beijing Chaoyang Hospital, Capital Medical University, Beijing, China Agoritsas, Thomas; McMaster University, Department of Clinical Epidemiology and Biostatistics; University Hospitals of Geneva, Division of General Internal Medicine & Division of Epidemiology Vandvik, Per; Innlandet Hospital Trust-divisjon Gjøvik, Department of Medicine Perner, Anders; Copenhagen University Hospital Rigshospitalet, Dept. of Intensive Care 4131 Møller, Morten; Copenhagen University Hospital Rigshospitalet,
    [Show full text]
  • ERR-0107-2019 Table S5
    Table S5. Studies included in the systematic reviews with meta-analysis Diagnosis of Inclusion Intervention (I) and Cointerventions a Study n Characteristic of Exclusion criteria VAP criteria Control (C) groups and VAP Bundle b ICU/ patients Surgical ICU (I): Cointervention: Polyurethane- Patients transferred from other TaperGuard EVACTM tubes: cone shape cuff (I): hospitals, urgent intubation in equipped with SSD port, APACHE II: 22.6 ± 5.1 MV>48h, clinical wards other than ICU, history polyurethane and cone shape VAP bundle: ICU LOS: 15 ± 5 features (CPIS) and Age between 18 and of MV, pregnancy, HIV, cuff. - Head elevation of 45º. Duration MV: 11.6 ± 7.1 bacterial pathogens 80 yr requiring immunosuppression, Method of SSD: Intermittent Mahmoodpoor - Protocolized enteral feeding. 276 ≥104 CFU/ml in mechanical ventilation leukopenia, patient refusal, and every 6h et al, 2017 - Sedation with washout periods. quantitative culture for more than 72 hours acute respiratory distress - Oral hygiene with (C): from bronchoalveolar with placement of an syndrome. Patients who were (C): chlorhexidine. APACHE II: 21.4 ± 4.4 lavage. endotracheal tube receiving antibiotics at the time Conventional high-volume - Hand washing. ICU LOS: 18 ± 10 of intubation, and those who low-pressure endotracheal - Pantoprazol for stress ulcer Duration MV: 12.3 ± 10.5 need a PEEP>5cm H2O. tubes prophylaxis. ICUs at Harborview Cointervention: Polyurethane- Medical Center. (I): cuffed 1) a polyurethane-conical (I): Patients with out-of-hospital shaped cuffed tube VAP bundle: SAPS II: 60 ± 12 cardiac arrest. 2) a polyurethane- conical - Head elevation of 45º. ICU LOS: N/A Adults (>18 yr of age) Use of a non–study-designated shaped cuffed tube with - Protocolized enteral feeding.
    [Show full text]
  • Stress Ulcer Prophylaxis Clinical Guidelines
    Last Approval Date: November 2019 Policy Title: Pharmacist-Managed Stress Ulcer Prophylaxis Protocol Departments Affected: Pharmacy Page 1 of 5 Key Words: SUP, PPI, H2RA Reference #: 1835 I. PURPOSE: To ensure safe, evidence-based utilization of stress ulcer prophylaxis in the inpatient setting to prevent upper gastrointestinal bleeding while minimizing the associated adverse effects (Clostridium dificile colitis, nosocomial pneumonia, electrolyte abnormalities, vitamin deficiencies, drug interactions, thrombocytopenia, etc) through use of a standardized, pharmacist-managed protcol. II. POLICY: It is the policy of SHC to provide a process for pharmacists to discontinue or convert stress ulcer prophylaxis therapies (proton pump inhibitors to histamine-2 receptor agonists) in the inpatient setting to align with current practice guidelines and literature. Exclusions: Continuation of home therapy or PRN use in the inpatient setting Use of acid suppression therapy for treatment indications III. PROCEDURE: A. Evaluation 1. Pharmacists will screen patients receiving scheduled acid suppression therapy for indication at the time of order verification and on a daily basis thereafter. 2. If the indication for PPI or H2RA use is treatment as listed below, or the frequency is PRN (as needed), the pharmacist will not intervene. a. Zollinger-Ellison Syndrome b. Acute upper GI bleed c. Erosive esophagitis d. Helicobacter pylori treatment e. Gastric or duodenal ulcer f. Gastroesophageal Reflux Disease (GERD) g. Continuation of home therapy 3. If the indication for PPI or H2RA use is stress ulcer prophylaxis (SUP), pharmacists will perform a detailed review of the patient’s chart to determine whether the patient meets any of the following approved criteria for therapy4: a.
    [Show full text]
  • Stress Ulcer Prophylaxis in the Intensive Care Unit – Adult/Pediatric/Neonatal – Inpatient Clinical Practice Guideline
    Stress Ulcer Prophylaxis in the Intensive Care Unit – Adult/Pediatric/Neonatal – Inpatient Clinical Practice Guideline Note: Active Table of Contents – Click to follow link EXECUTIVE SUMMARY ........................................................................................................... 3 SCOPE ...................................................................................................................................... 4 METHODOLOGY ...................................................................................................................... 4 DEFINITIONS ............................................................................................................................ 5 INTRODUCTION ....................................................................................................................... 5 RECOMMENDATIONS – ADULT ICU PATIENTS .................................................................... 8 RECOMMENDATIONS – PEDIATRIC ICU PATIENTS ............................................................10 RECOMMENDATIONS – NEONATAL ICU PATIENTS ............................................................10 RECOMMENDATIONS – ADULT, PEDIATRIC, AND NEONATAL ICU PATIENTS ................12 UW HEALTH IMPLEMENTATION ............................................................................................13 APPENDIX A ............................................................................................................................14 REFERENCES .........................................................................................................................15
    [Show full text]
  • Original Article Perioperative Application of Proton Pump Inhibitors to Prevent Stress Ulcer
    Int J Clin Exp Med 2016;9(8):16771-16776 www.ijcem.com /ISSN:1940-5901/IJCEM0028559 Original Article Perioperative application of proton pump inhibitors to prevent stress ulcer Yanhong Wang, Weijuan Song Department of Pharmacy, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China Received March 17, 2016; Accepted June 12, 2016; Epub August 15, 2016; Published August 30, 2016 Abstract: Background: Patients with surgeries are prone to the occurrence of stress ulcer when under the stress sta- tus. Currently, proton pump inhibitors (PPI) are often used in clinical surgeries to prevent stress ulcer (SU). Purpose: To assess the rationality of perioperative application of PPI to prevent SU. Methods: Two hundred and thirty-eight patients performing surgeries in the department of vascular surgery were enrolled in this study, and 204 patients applied PPI to prevent the perioperative SU. Their basic situations and rationalities of PPI application in these 204 patients were analyzed. Results: The ratio of perioperative PPI application in preventing SU was 85.71% (204/238), while only 47.06% (96/204) of patients had the risk factors of SU. 96.08% (196/204) of administration routes were intravenous. 87.06% (222/255) of PPI injection medical orders selected normal saline as appropriate solvent of PPI. The problems such as too large dosage, long duration and frequent medication-change still existed for PPI application. Conclusion: When applying PPI to prevent SU, there still exist further optimization in aspects such as indications,
    [Show full text]